Skip to main content
. 2021 Sep 20;12:705154. doi: 10.3389/fendo.2021.705154

Figure 5.

Figure 5

Establishment of diabetic cardiomyopathy mouse model. (A) Schematic illustration of diabetic cardiomyopathy mouse model. (B–D) Body weight, random blood glucose, and heart weight/body weight at 26 weeks after STZ injection (n=6 each). (E) Representative images of H&E staining and WGA staining in the hearts of CON and DbCM mice (n=6; scale bar, 50 μm). (F) Statistical results of the myocyte cross-sectional areas of H&E staining (n=6, at least 100 cells per mouse were analyzed). (G) Quantitative analysis of myocyte cross-sectional areas of WGA staining (n=6, at least 100 cells per mouse were analyzed). (H) Representative echocardiographic M-mode images. (I) Echocardiographic measurements of LVEF. (J) Echocardiographic measurements of FS. (K–M) Representative RNA expression of ANP, BNP, and β-MHC, respectively. Data are shown as mean ± SD (n=6 each). *p < 0.05, **p < 0.01 vs CON group (student t-test). CON, control mice without diabetes; DbCM, diabetic cardiomyopathy; STZ, streptozotocin; H&E, hematoxylin eosin; WGA, wheat germ agglutinin; LVEF, left ventricle ejection fraction; FS, fractional shortening; ANP, atrial natriuretic peptide; BNP, B type natriuretic peptide; β-MHC, β-myosin heavy chain.